About Dylan Smith

This author has not yet filled in any details.
So far Dylan Smith has created 61 blog entries.

Aculabs utilizes rapid flu kits to help long-term care providers meet testing demands during flu season

Aculabs offers clients access to purchase CLIA-waived rapid flu testing kits, with each kit priced at $325 (subject to tax and credit card processing fee). Each test kit comes with 25 flu tests, amounting to roughly just $13 cost per test. By utilizing such test kits, and ensuring their accessibility for clients to purchase,

By |2024-03-08T11:14:27-05:00January 3rd, 2023|Categories: News|0 Comments

Aculabs celebrates 50 years dedicated to service with integrity

This week of September 12th, Aculabs officially celebrates its 50th anniversary in operations, and Dauna Gudaitis, our corporate secretary, and the company's co-founder, has been preparing for this moment throughout the last year. The company was started by Algird V. Gudaitis, BLD, the late husband of Dauna Gudaitis, back in 1972 out of Fair

By |2022-09-26T10:45:56-04:00September 12th, 2022|Categories: News|0 Comments

Healthcare providers urge Congress to Replenish the HRSA Uninsured Relief Fund

Led by the American Clinical Laboratory Association (ACLA), over 60 public health organizations representing patients, health care professionals, hospitals, public health, laboratories, and diagnostic manufacturers have sent a letter urging the U.S. Congress to replenish the HRSA COVID-19 Uninsured Relief Fund.Click here to view the letter sent by the ACLA and others to Congressional leadership.The Health

By |2024-01-31T10:41:53-05:00May 12th, 2022|Categories: News|0 Comments

Aculabs rolls out updates to Online Order web portal tools

The start of 2022 saw Aculabs roll out several new features to our online web portal, including Email Reporting for Result Notification and improved logic used in our Exception Test Flagging feature. The purpose of such functionality is to continue expanding the ways Aculabs communicates with your staff while tackling patient care. Such features

By |2022-10-28T09:34:15-04:00April 21st, 2022|Categories: News|0 Comments

QuantiFERON-TB Gold Plus now performed as in-house testing

Aculabs will be offering QuantiFERON-TB Gold Plus in-house as of April 6, 2022; the test provides highly accurate and reproducible results, single-step testing, and innovative CD8 T cell technology that provides a more comprehensive view of the immune response to TB infection. Letter from the Director: QuantiFERON-TB Gold Plus testing offers accuracy in health

By |2023-01-06T17:43:34-05:00April 14th, 2022|Categories: News|0 Comments

Letter from the Director: QuantiFERON-TB Gold Plus testing offers accuracy in health monitoring for patients

Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (Mtb). A person infected with MTB might end up with TB disease with clinical, radiographic, and microbiological evidence of tuberculosis, or will have no clinical evidence of TB disease and would be considered latent tuberculosis infection (LTBI); however, about 10% with LTBI will progress or

By |2022-04-21T15:41:20-04:00April 14th, 2022|Categories: Quarterly Letter|Comments Off on Letter from the Director: QuantiFERON-TB Gold Plus testing offers accuracy in health monitoring for patients

Supply Shortage on Grey & Pink Para-Paks to Impact Testing

Please be aware that several send-out tests will be temporarily unavailable to order, as supply shortages impacting the grey and pink parapak kits used for the collection of stool specimen have impacted the reference laboratories in which Aculabs utilizes for such send-out testing. The following are the most commonly ordered tests to be impacted:

By |2022-04-21T15:29:58-04:00March 17th, 2022|Categories: News|0 Comments

New Updates to Aculabs Online Order Entry System

As an industry leader, Aculabs values the way in which our digital and technological systems can always be improved to continually optimize the user experience. Our Online Web Portal remains the main hub for which many clients can 1) most easily place orders and 2) receive order results in the shortest time possible, necessary

By |2022-09-26T10:59:53-04:00January 6th, 2022|Categories: News|0 Comments

FDA Warns of Reduced Sensitivity for Omicron in Rapid Tests

In a new memo, the United States Food & Drug Administration (FDA) has documented and warned both patients and healthcare providers of the risk of Omicron, the latest variant of SARS-CoV-2, displaying reduced sensitivity to rapid antigen tests. Rapid antigen tests, sometimes referred to as lateral flow tests, are often used in occupational and

By |2021-12-29T11:19:27-05:00December 29th, 2021|Categories: News|0 Comments
Go to Top